Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.

Date publication

août 2017

Journal

Breast cancer research : BCR

Auteurs

Membres identifiés du Cancéropôle Est :
Pr FUMOLEAU Pierre , Dr PAGET-BAILLY Sophie , Pr PETIT Thierry , Pr PIVOT Xavier , Dr RIOS Maria , Dr JOUANNAUD Christelle , Mme HENRIQUES Julie

Tous les auteurs :
Curtit E, Pivot X, Henriques J, Paget-Bailly S, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Thomas G, Deleuze JF, Pauporté I, Romieu G, Cox DG

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28830573

Résumé

Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combined effect of the 94 risk alleles can be calculated to measure the global risk of breast cancer. We aimed to test the hypothesis that the 94-SNP-based risk score is associated with clinico-pathological characteristics, breast cancer subtypes and outcomes in early breast cancer.

Mots clés

Breast cancer, Genetic variant, Prognosis, Risk score, Single nucleotide polymorphism

Référence

Breast Cancer Res.. 2017 Aug;19(1):98